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Here we report that administration of retinoids can alter the outcome of an acute murine cytomegalovirus
(MCMV) infection. We show that a crucial viral control element, the major immediate-early enhancer, can be
activated by retinoic acid (RA) via multiple RA-responsive elements (DR2) that bind retinoid X receptor-
retinoic acid receptor (RAR) heterodimers with apparent dissociation constants ranging from 15 to 33 nM.
Viral growth is dramatically increased upon RA treatment of infected tissue culture cells. Using synthetic
retinoid receptor-specific agonists and antagonists, we provide evidence that RAR activation in cells is required
for mediating the response of MCMV to RA. Oral administration of RA to infected immunocompetent mice
selectively exacerbates an infection by MCMV, while cotreatment with an RAR antagonist protects against the
adverse effects of RA on MCMV infection. In conclusion, these chemical genetic experiments provide evidence
that an RAR-mediated pathway can modulate in vitro and in vivo infections by MCMV.
Retinoids, a group of vitamin A derivatives, have been found
to play important roles in development, growth, reproduction,
vision, and general homeostasis of numerous tissues. The cel-
lular responses to extracellular retinoids are mediated princi-
pally by members of the steroid-thyroid superfamily of intra-
cellular hormone receptors, which include the retinoic acid
(RA) receptors (RARs) and the retinoid X receptors (RXRs)
(reviewed in reference 12). The RAR subfamily binds two
naturally occurring ligands, all-trans-RA (ATRA) and 9-cis-
RA, whereas RXR subfamily members bind 9-cis-RA exclu-
sively (12, 34). These particular receptors are nuclear proteins
that, upon ligand activation, function as heterodimeric tran-
scription factors to control expression of target genes by bind-
ing to specific DNA sequences, termed RA response elements
(RAREs) (reviewed in reference 34). In addition, these two
families of nuclear receptors may indirectly influence biologi-
cal processes by remodeling chromatin, interacting with tran-
scriptional coregulators, or cross-talking with other signalling
pathways (12, 13, 24, 29, 50).
In response to environmental stimuli, intracellular signalling
events can play an important role in modulating the outcome
of an infection. In this regard, recent findings from in vitro
studies point toward a functional link between a diverse group
of pathogenic viruses and a direct or indirect component of the
vitamin A signalling pathway (reviewed in reference 20). Ex-
amples of these viruses include human papillomavirus, Ep-
stein-Barr virus, human cytomegalovirus (HCMV), hepatitis B
virus, and human immunodeficiency virus. However, the elab-
oration and extent to which extracellular agents (such as reti-
noids) drive or restrict the infectious program of a virus are not
well understood. Elucidating host cell-virus interactions that
determine the outcome of virus infection is central to under-
standing the processes of viral pathogenesis. To this end, we
have investigated the involvement of retinoids in modulating
the CMV infectious program. Retinoids are known to influ-
ence HCMV at a variety of different levels in vitro. For in-
stance, exposure of cells to RA can enhance viral gene expres-
sion and the susceptibility to infection via differentiation- and
nondifferentiation-driven events (3–5, 21, 22, 30, 40) and can
reactivate viral expression in latently infected tissue culture
cells (51). At the level of viral gene expression, the HCMV
genome depends on a hierarchy of interactions among the
host-encoded and viral immediate-early (IE) genes in the in-
fected cell. In this regard, the HCMV major IE promoter
(MIEP) has been shown to respond to physiological concen-
trations of RA via three high-affinity binding sites for RXR-
RAR heterodimers (6, 19). The biological significance of the
HCMV MIEP in vivo is underscored by transgenic animal
model systems which show that the pattern of expression con-
trolled by the HCMV MIEP corresponds to sites of natural
infection in humans (9, 26). This pattern of expression and
cellular sites of natural infection closely overlaps with the cell-
specific distribution pattern of RARs (8). Taken together,
these studies indicate that RA may indirectly or directly affect
HCMV, and hence they predict the potential influence of RA
in altering a CMV infection in vivo. The question of whether
retinoids have any impact on the infectious disease process
remains open because of the species-specific restriction in the
ability of HCMV to replicate. Infection of mice with murine
CMV (MCMV) has provided a good model to study the patho-
genesis of CMV. We have therefore studied the effect of reti-
noids on MCMV infection in vitro and in vivo.
Here, we present evidence that MCMV is susceptible to
regulation by natural and synthetic retinoids at a number of
different levels. We show that in tissue culture cells RA can
activate the MCMV enhancer and can also selectively promote
viral growth. The stimulatory effects of RA on enhancer activ-
ity and viral growth can be prevented by treatment with an
RAR-specific antagonist. In vivo, we demonstrate that oral
administration of RA to infected mice worsens an acute infec-
tion by MCMV but not other pathogenic viruses. By contrast,
we provide evidence that oral dosage of an RAR antagonist to
infected mice can protect against the adverse effects of RA in
MCMV infection. These observations thus define a novel
pathogenetic pathway in the infectious program of CMV and
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have important implications for understanding control mech-
anisms of viruses outside immunoregulatory pathways.
MATERIALS AND METHODS
Cells and viruses. NIH 3T3 murine fibroblasts, NT-2/D1 human teratocarci-
noma cells, TK2143B human osteosarcoma cells, and Vero cells were propa-
gated in Dulbecco’s modified essential medium (DMEM) supplemented with 2
mM glutamine, 100 U of penicillin per ml, 100 mg of gentamicin per ml, and 10%
fetal bovine serum, except for the NIH 3T3 cells, for which 10% calf serum was
used. The Smith strain of MCMV used in this study was kindly provided by Ann
Campbell (Eastern Virginia Medical School). RM408, RM427, and RM461
MCMV recombinants were originally obtained from Edward Mocarski (Stanford
University). RM408 carries the lacZ gene under control of the MCMV MIEP-
enhancer (nucleotides 2146 to 150) inserted in place of a 79-bp HpaI fragment
in the ie2 promoter (35). RM461 and RM427 each carry the lacZ gene under
control of the HCMV MIEP-enhancer (nucleotides 2219 to 219). In RM461,
the insertion is in a HindIII site between sgg1 and ie2 (48). In RM427, the
insertion replaces a 79-bp fragment between two HpaI sites in the ie2 promoter
(48). In addition, RM427 carries a spontaneous 323-nucleotide deletion in the
sgg1 gene. Stocks of tissue-propagated MCMVs were prepared in and titers were
determined by standard plaque assay on NIH 3T3 cells. For in vivo assays,
salivary gland-passaged MCMV was used. Salivary glands from weanling BALB/
c.ByJ mice inoculated intraperitoneally with 103 PFU of MCMV were harvested
on day 15 of infection, homogenized in a 10% suspension, and cleared by
centrifugation. The vaccinia virus strain WR and herpes simplex virus type 1 used
in these studies were initially obtained from Persephone Burrow and Pietro
Sanna (The Scripps Research Institute), respectively. Viral stocks for vaccinia
virus WR and herpes simplex virus type 1 were prepared and viral titers were
determined by standard plaque assay on human TK2143B and Vero cells, re-
spectively.
Retinoids. ATRA was purchased from Sigma Chemical Co. (St. Louis, Mo.).
9-cis-RA and LG100069 {4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naph-
thyl)ethenyl]benzoic acid} were provided by Rich Heyman (Ligand Pharmaceu-
ticals Inc., San Diego, Calif.). TTNPB {(E)-4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tet-
rahydro-2-naphthalenyl)-1-propenyl]benzoic acid} was prepared as described by
Loeliger et al. (33). The RAR antagonist AGN 193109 {4-[(5,6-dihydro-5,5-
dimethyl-8-(4-methylphenyl)-2-naphthalenyl)-ethynyl]benzoic acid} was synthe-
sized as described by Johnson et al. (23). For cell culture assays, retinoid stock
solutions (10 mM) were made in dimethyl sulfoxide and/or ethanol and stored
under argon at 270°C. Further dilutions were made in DMEM supplemented
with charcoal resin-treated serum before use, except in the experiments shown in
Fig. 4A and B, where the serum was not charcoal treated. For animal treatments,
retinoids were prepared as a suspension in corn oil (50 mg of ATRA per kg of
body weight and 25 mg of AGN 193109 per kg) immediately before use. Control
animals received the corn oil alone. All retinoids were handled under subdued
lighting.
Plasmid constructions and transfections. The reporter constructs pON405,
containing MCMV MIEP-enhancer sequences from position 22000 to 150
relative to the start site, and pON407, containing 196 bp of the MCMV MIEP-
enhancer (from position 2146 to 150 relative to the start site) linked to the
Escherichia coli lacZ indicator gene were kindly provided by Edward Mocarski
(11, 35). The reporter plasmids MDR2a and MDR2b, encoding the two different
RAREs, were constructed by inserting the double-stranded oligonucleotides
59-TATTGACCTTTTGTACTGGG-39 (MDR2a) and 59-TATTGACCTTATG
TACGTGC-39 (MDR2b) at the HindIII-BamHI sites upstream of the herpes
simplex virus thymidine kinase gene promoter, tkCAT (pRSCAT4 [49]). The
b-galactosidase expression vector RSVbgal and the luciferase expression vector
tkLuc were used as internal controls in transfection assays (6).
Transfections were performed by the calcium phosphate coprecipitation
method as previously described (19). Cellular extracts were prepared as de-
scribed previously and assayed for b-galactosidase, luciferase, or chloramphen-
icol acetyltransferase (CAT) activity (6). b-Galactosidase activity was expressed
as the normalized response, which is the b-galactosidase activity divided by the
luciferase activity. For the CAT assays, cell extracts containing the same amount
of b-galactosidase activity were used. The CAT activity was quantitated by using
a Molecular Dynamics Phosphorimager system with ImageQuant software.
DNA binding assays and determination of the apparent equilibrium dissoci-
ation constant. The human RARb and RXRb proteins were expressed in the
baculovirus system as previously described (10). Binding reactions were per-
formed as described by Angulo et al (6) with recombinant RARb and RXRb and
0.2 to 0.8 ng of 32P-labeled annealed MDR2a or MDR2b oligonucleotide probe.
Gels were imaged and quantitated by using a Molecular Dynamics Phosphor-
Imager system with ImageQuant software. The apparent equilibrium dissociation
constants (KDs) for the RXR-RAR-DNA complex for sites MDR2a and MDR2b
were determined by equilibrium binding analyses. A series of standard binding
reaction mixtures containing a constant amount of RXR and/or RAR were
incubated with increasing concentrations of double-stranded MDR2a or MDR2b
oligonucleotides. Bound and free DNAs were separated by electrophoretic mo-
bility shift assay (EMSA), and the radioactivity in each fraction was quantitated.
Data were plotted as 1/[bound DNA] versus 1/[free DNA]. The y intercept of
such a plot is 1/[active protein]. The slope of this plot is the apparent KD divided
by the concentration of active protein. In this analysis, the value of the apparent
KD is only an estimate of the true KD, since the nonspecific binding of protein
with the poly(dI-dC) present in each reaction mixture and the potential disso-
ciation of the receptor-DNA complex in the gel are not taken into account.
In vitro infections. NIH 3T3 cells (approximately 3 3 105 per well of six-well
plates) were exposed to the different retinoids or the vehicle in DMEM supple-
mented with 3% charcoal resin-treated calf serum for 4 h and were infected with
MCMV at the different multiplicities of infection (MOIs) indicated in the figure
legends (ranging from 0.01 PFU per cell in the multistep growth curves to 10
PFU per cell for single-step growth curves). After a 1-h adsorption period, the
virus inoculum was removed, the cultures were washed three times with phos-
phate-buffered saline, and fresh DMEM supplemented with 3% charcoal resin-
treated serum containing the retinoids or the solvent alone was added. Every 24 h
after infection, the cultures were fed with fresh medium containing the retinoids
or the solvent. At different times after infection, the supernatants of three
independent cultures were harvested, frozen, and thawed, and the infectious
virus was quantitated by standard plaque assay on NIH 3T3 cells. Vaccinia virus
and herpes simplex virus type 1 infections of NIH 3T3 cells were carried out in
the same manner as described above for MCMV infections, using an MOI of 0.01
PFU per cell and DMEM supplemented with 3% charcoal resin-treated calf
serum containing the retinoids. Infectious vaccinia virus from cellular extracts
and cell-free herpes simplex virus type 1 in the cultures were quantitated by
standard plaque assay on TK2143B and Vero cells, respectively.
Mouse treatments and in vivo infections. Six-week-old female BALB/c.ByJ
mice from the Scripps Research Institute breeding colony were used under
specified pathogen-free conditions. Mice were treated by intragastric intubation
with 200 ml of corn oil or the different retinoids (50 mg of ATRA per kg and/or
25 mg of AGN 193109 per kg) in corn oil 2 h prior to infection and on days 2, 4,
7, 9, 11, and 14 after infection. Animals were injected intraperitoneally with
various amounts of salivary gland passage MCMV (Smith strain). When the viral
load in spleens was analyzed, 4 days after inoculation, mice (five per group) were
euthanized and their spleens were removed, weighed, and harvested as a 10%
(wt/vol) tissue homogenate, and virus titers were determined on NIH 3T3 cells by
standard plaque assay. To compare levels of lethality of MCMV in mice treated
with the different retinoids and those treated with the solvent alone, infected
animals were observed daily and monitored for death up to and including day 15
postinoculation. In a first set of experiments, the 50% lethal dose (LD50) was
calculated by the method of Reed and Muench (42), using six mice per group and
serial fivefold dilutions of MCMV (ranging from 5 3 103 to 1 3 106 PFU/mouse).
In a second set of experiments (shown in Fig. 7), a logit regression curve, relating
survival to log dose of virus, was fit to each group (three to six mice per group),
and the LD50 was estimated for each group from the logit regression model (14).
In this case, the virus dose ranged from 3 3 104 to 3 3 105 PFU/mouse in steps
of 1 3 104 in the group of animals treated with ATRA, whereas in the group of
animals treated with solvent alone, the virus dose ranged from 9 3 104 to 8 3 105
PFU/mouse, again in steps of 1 3 104. Vaccinia virus infections were carried out
in a manner similar to that described above for the MCMV infections.
Histopathology. Organs for histological sections were fixed in Bouin’s solution
before being dehydrated and embedded in paraffin by standard procedures.
Sections (7 mm thick) were cut with a rotary microtome and stained with hema-
toxylin and eosin for examination.
RESULTS
Positive regulation of the MCMV enhancer by RA. As a first
step in exploring the role of retinoids in modulating MCMV,
we examined the ability of its MIEP-enhancer to be regulated
by RA. To test this possibility, we used a recombinant plasmid
(pON405) containing the murine MIEP-enhancer that regu-
lates expression of the bacterial lacZ reporter enzyme, b-ga-
lactosidase. The reporter plasmid was initially tested for RA
responsiveness after transient transfection into human embry-
onal teratocarcinoma NT-2/D1 cells. NT-2/D1 cells endog-
enously express unstimulated levels of retinoid receptors
(RARs and RXRs) that can efficiently transactivate reporter
plasmids containing high-affinity binding sites for RAR-RXR
heterodimers (6, 44). In these experiments, ATRA selectively
induced (6- to 10-fold) the expression from the MIEP-contain-
ing reporter construct in a concentration-dependent manner
(Fig. 1A and B and data not shown). The murine MIEP re-
sponded to ATRA with a half-maximal response at ;5 nM
ATRA, suggesting the physiological significance of the ob-
served RA induction (data not shown).
To determine whether the selectivity of the ATRA induction
is dependent on the enhancer sequences, we analyzed a dele-
tion mutant of the MIEP reporter construct that has previously
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been shown to eliminate enhancer activity in the transient-
expression assay (15). Truncation of the MIEP reporter con-
struct at nucleotide position 2146 abolished the response to
ATRA (Fig. 1A and B), suggesting that enhancer sequences
located upstream of position 2146 mediate a stimulatory effect
of ATRA on the murine MIEP. Inspection of this sequence
region revealed 10 candidate direct repeat sequences that
closely resemble RAREs, with their tandem repeats separated
by 2 nucleotides. Previous studies have shown that a responsive
element for ATRA is composed of tandem repeats of the
canonical half-site AGGTCA, in which optimal receptor bind-
ing is determined by a spacer of 2 (DR2 element) or 5 (DR5
element) nucleotides between each half-site (12). Seven of
these putative RAREs are located within the boundaries of the
defined enhancer domain (15) and on the basis of sequence
homology can be grouped into two types of elements, named
MDR2a and MDR2b (a schematic representation of these
sites is shown in Fig. 1A). In comparison with the consensus
core motif (59-A/GGT/GTCA-39), MDR2a repeats show the
best match, with 92% identity, while MDR2b elements have an
83% match to the consensus sequence. To investigate whether
these elements could confer ATRA inducibility on an heterol-
ogous promoter, a single copy of MDR2a and MDR2b se-
quences was individually transferred to the herpes simplex
virus thymidine kinase promoter, which is nonresponsive to
ATRA. The transcriptional activities of these reporter con-
structs, in the absence and presence of ATRA, were investi-
gated in the transient-transfection assay. Single copies of both
MDR2a and MDR2b elements were able to confer ATRA
inducibility to the herpes simplex virus thymidine kinase pro-
moter (Fig. 1C and D). In comparison with the MDR2b ele-
ment, the MDR2a element confers a stronger response to
ATRA (Fig. 1C and D). These data provide evidence that the
MCMV enhancer contains at least seven RAREs of the DR2
configuration and suggest that these elements might directly
interact with RXR-RAR heterodimers.
Accordingly, EMSAs with 32P-labeled DNA probes were
used to demonstrate a direct interaction between the MDR2a
and MDR2b elements and purified recombinant RAR and
RXR proteins. Under the conditions used in these experi-
ments, RAR and RXR alone weakly bind the DNA probes but
a major DNA complex could be formed when the probes were
FIG. 1. RAREs in the MCMV enhancer. (A) Schematic representation of the MCMV MIEP sequence from position 22000 to 150 present in the reporter construct
pON405. The locations of the seven potential RAREs are marked by open boxes. The AGGTCA-related motifs of the two types of elements, named MDR2a and
MDR2b, are indicated. The numbers refer to the nucleotide position relative to the transcription start site. A schematic of the MCMV MIEP deletion mutant present
in the reporter construct pON407 in which sequences from position 2146 to 22000 are abolished is shown below. One copy each of MDR2a and MDR2b was
independently transferred to the heterologous promoter of the CAT gene expression vector tkCAT to generate the reporter plasmids MDR2a and MDR2b shown in
the lower portion. (B) NT-2/D1 cells were transfected with 5 mg of either the pON405 or pON407 reporter plasmid and incubated for 36 h with 1025 M ATRA (1)
or the vehicle (2). Transfection efficiency was standardized by cotransfection of 5 mg of tkLuc. The fold induction of b-galactosidase activity was calculated for each
construct by taking the activity in the absence of ATRA as 1. Data shown represent the means and standard deviations of triplicate determinations. (C) Five micrograms
of the reporter plasmids MDR2a and MDR2b was cotransfected with 5 mg of the b-galactosidase pRSVbgal internal control expression vector into NT-2/D1 cells and
then treated for 36 h with 1025 M ATRA (lanes 1) or with vehicle (lanes 2). The figure shows the result of a representative assay for CAT enzyme activity from cell
lysates. Similar results were obtained in three independent experiments. (D) The response of MDR2a and MDR2b to RA (b1) is plotted as the normalized activity
observed in these experiments, calculated for each construct by taking the activity in the absence of ATRA (2) as 1.
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incubated with both RAR and RXR (Fig. 2A), indicating that
MDR2a and MDR2b bind RXR-RAR heterodimers more ef-
ficiently than either RXR or RAR homodimers. The het-
erodimeric complex could be specifically competed by unla-
beled probe but not by a nonspecific oligonucleotide (data not
shown). We next sought to investigate the binding affinity of
the RAR-RXR heterodimers to the MDR2a and MDR2b sites
by determining the apparent equilibrium dissociation constant
(KD) of heterodimers to each site by using the EMSA system.
The apparent KD measurements derived from double-recipro-
cal plots of RXR-RAR binding reactions were 15 and 33 nM
for MDR2a and MDR2b, respectively (Fig. 2B). The binding
constants for receptor heterodimers bound to these elements
are within the physiological concentration range of these nu-
clear receptor proteins. In good agreement, the strengths of
MDR2a- and MDR2b-mediated RA activation in cells (Fig.
1D) correlate with the affinity to which they bind RXR-RAR
heterodimers (Fig. 2B). Taken together, these experiments
provide evidence to support the conclusion that the viral en-
hancer binds RXR-RAR in vivo.
While the data presented above clearly show that RAR and
RXR can regulate the viral enhancer, they do not address
whether RA is able to exert control of the enhancer during an
infection. To demonstrate that the enhancer can be regulated
by RA in the context of an infection, we carried out infection
experiments with MCMV recombinants containing an inser-
tion of a lacZ reporter gene under the control of either the
HCMV or MCMV MIEP. The segment of the HCMV MIEP
(nucleotides 2219 to 219) present in RM461 and RM427
recombinant viruses and the segment of the MCMV MIEP
(nucleotides 2146 to 150) present in RM408 recombinant
virus have been shown to be nonresponsive to ATRA and
9-cis-RA (6) (Fig. 1A and B). In the recombinants RM408 and
RM427, the lacZ reporter gene is positioned in the immediate
vicinity of the endogenous MCMV enhancer, and its expres-
sion has been shown to be controlled by the enhancer (35)
(Fig. 3A). By contrast, in the recombinant RM461 virus, the
lacZ reporter is positioned in a locus outside the influence of
the MCMV enhancer (48) (Fig. 3A). Thus, these recombinants
contain lacZ inserts in which their different positions in the
genome determine their differential responsiveness to regula-
tion by the enhancer. If the endogenous MCMV enhancer is
responsive to RA, reporter gene activity would be enhanced by
RA in RM408- and RM427-infected cells but not in RM461-
infected cells. In the experiment whose results are shown in
Fig. 3B, murine NIH 3T3 fibroblasts were infected with either
RM408, RM427, or RM461 and were exposed to 9-cis-RA or
the vehicle alone, and the amount of b-galactosidase activity
present in each infection was quantitated. As predicted, infec-
tion of cells with RM408 and RM427 showed increased (three-
to fivefold) levels of reporter gene activity upon exposure to
9-cis-RA, while the reporter gene activity in RM461-infected
cells remained unchanged (Fig. 3B). These results indicate that
RA can stimulate the enhancer activity of MCMV in the con-
text of an infection.
RA enhances the growth of MCMV in tissue culture. We
next evaluated the potential role of RA in influencing viral
growth. For this purpose, NIH 3T3 cells were infected with
MCMV at an MOI of 0.01 in the presence and absence of
9-cis-RA, and the amount of infectious virus produced was
determined by plaque assay at different times postinfection. As
shown in Fig. 4A, the rate of growth exhibited by MCMV
increased markedly in the presence of 9-cis-RA or ATRA (see
also Fig. 5B, and data not shown). The magnitude of this
response varied from a 20- to 100-fold enhancement in growth
yield. The growth response of MCMV to 9-cis-RA is selective,
as growth of vaccinia virus and herpes simplex virus (two vi-
ruses for which functional RAREs in their genomes have not
been described) in NIH 3T3 cells is unaffected by treatment
with exogenous 9-cis-RA (Fig. 4C and D).
In the type of growth curve examined as described above, the
yield of virus at the various harvesting points reflects a cumu-
lative rate of growth from multiple rounds of replication and
infection in the culture. To determine the level of growth rate
FIG. 2. Binding of RAR-RXR heterodimers to the MCMV enhancer
RAREs. (A) Baculovirus-derived preparations of RARb or RXRb were incu-
bated either independently or in combination with 32P-labeled probes represent-
ing the MDR2a and MDR2b elements and analyzed in a gel mobility retardation
assay. The arrow indicates the major specific nucleoprotein complex detected.
(B) The apparent dissociation constants (KD) were determined by using double-
reciprocal plots (see Materials and Methods for details). The figure shows the
results of a representative experiment, and the apparent KD data represent
average values from three separate determinations.
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enhancement in a single round of infection, a one-step growth
analysis of MCMV in the presence and absence of exogenously
added 9-cis-RA was performed. In this experiment, the cul-
tures were infected with an MOI of 10 to ensure that 100% of
the cells were infected. Figure 4B shows that in a single-step
growth analysis, 9-cis-RA treatment results in an approxi-
mately eightfold enhancement in growth of MCMV. The
greater RA-induced enhancement of MCMV growth at low
MOI than at high MOI is most likely attributable to a cumu-
lative effect from multiple rounds of replication in the multi-
step growth curve. However, it is possible that an IE protein
could be required for viral growth at low MOI but may play
less of a role at high MOI, as has been suggested for HCMV
(38). A similar fold enhancement in viral multiplication at high
MOI is also observed upon administration of ATRA (data not
shown). In this regard, it is noteworthy that while ATRA binds
only RARs, in living cells it can be converted to 9-cis-RA,
which binds and activates both RARs and RXRs. Taken to-
gether, these results are consistent with the suggestion that
retinoid-induced MCMV multiplication is mediated by RARs
and/or RXRs.
Response of MCMV to RAR-specific and RXR-specific li-
gands. We next sought to explore whether an RAR or an RXR
agonist is sufficient to mediate the increased growth and en-
hancer activation. For these experiments we used the metabol-
ically stable RA analogs TTNPB and LG100069, which are
known to be highly selective and potent ligands for the RAR
and RXR families, respectively (10, 28). These synthetic reti-
noids eliminate complications resulting from interconversion
and cross-receptor binding encountered with the natural reti-
noids. Accordingly, we analyzed the ability of these synthetic
retinoids to activate reporter constructs containing the viral
enhancer in transfection assays. Figure 5A shows that en-
hancer activity could be stimulated by 9-cis-RA (sevenfold),
ATRA (sevenfold), and TTNPB (sixfold) but not LG100069
(,twofold), indicating the requirement for RAR ligand acti-
vation functions to mediate transcriptional enhancement. This
result is consistent with our previous studies showing that the
RXR partner of an RXR-RAR heterodimer bound to the
HCMV enhancer RAREs is unable to activate transcription on
its own (3, 6). To investigate whether RXR can contribute to
enhancer activation, the RAR- and RXR-specific ligands were
simultaneously added, and the resulting transcriptional activa-
tion was compared with that obtained with TTNPB alone.
Figure 5A shows that a small enhancement in the efficacy of
TTNPB activation was elicited in the presence of LG100069.
These results suggest that RXR activation can play a role in
modulating RA activation of the enhancer, although the re-
sponse appears to be highly dependent on RAR transactiva-
tion functions.
To determine whether activation of RAR or RXR also plays
a differential role in regulating MCMV growth, we evaluated
viral growth in the presence of the various synthetic ligands. In
these experiments, NIH 3T3 cells were infected with MCMV at
an MOI of 0.01 in the presence of the different synthetic
retinoids. Figure 5B shows that MCMV growth could be stim-
ulated by TTNPB (11-fold) but not LG100069 (less than
2-fold), demonstrating the inability of RXR to exclusively con-
tribute to ligand activation and indicating that an RAR-in-
duced pathway is sufficient for mediating induction of MCMV
growth. When TTNPB and LG100069 were added together, a
higher level of MCMV growth (22-fold) was induced than with
TTNPB alone (Fig. 5B). The combination of TTNPB and
LG100069 induced viral growth to levels comparable to those
found for 9-cis-RA (21-fold) or ATRA (25-fold), thus suggest-
ing that RXR activation plays a role in the presence of a
transcriptionally active RAR. These results lead us to propose
that the RAR pathway plays the predominant role in promot-
ing viral growth by RA.
An RAR-selective antagonist can block the response of
MCMV to RA. To establish that activation of RAR by RA
leads to an increase in enhancer activity and viral growth, we
next tested whether a synthetic antagonist selective for RAR is
able to suppress the stimulatory effects of RA. A number of
retinoid antagonists have been described and shown to specif-
ically block RAR activation by exogenous agonists in vitro (2,
7, 16, 17, 23, 31, 45–47, 52). One of these compounds, AGN
193109 (Fig. 5C), which binds all three RAR subtypes with
affinities in the low-nanomolar range, has been shown to be a
potent inhibitor of RA activation (23). Recent studies with this
compound have shown that it can not only antagonize RA
activation as a competitive inhibitor (neutral antagonist) but
also inhibit the basal gene transcriptional activity of unligan-
FIG. 3. Activation of the MCMV enhancer by RA in the context of the
infection. (A) A schematic representation of the HindIII map of the MCMV
genome is shown on the top line. The HindIII-J, -K, and -L fragments have been
expanded to show the region containing the MIE genes (ie1, ie2, and ie3) and the
sgg1 gene. The hatched box depicts the murine MIEP-enhancer (Enh.). The
recombinant viruses RM408, RM427, and RM461, which carry an insertion of
the lacZ reporter gene, are shown in the lower portion. The position and orien-
tation of the insertion for each virus are shown. The black box depicts the HCMV
promoter-enhancer sequences from position 2219 to 219. The empty box de-
picts position 2146 to 150 from the MCMV promoter-enhancer. Wt, wild type.
(B) NIH 3T3 cells were exposed to 9-cis-RA (1025 M) (1) or the vehicle (2),
infected with MCMV recombinant RM408, RM427, or RM461 at an MOI of 0.1
PFU/cell, and assayed 48 h later for b-galactosidase activity. Shown is the nor-
malized b-galactosidase activity observed in these experiments, calculated in
each case by taking the activity in the absence of RA as 1. Error bars indicate
standard deviations.
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ded RAR and hence function as an inverse agonist (25). When
increasing amounts of the RAR antagonist were added to a
fixed concentration of 9-cis-RA, the degree of transcriptional
activation from the MCMV enhancer was inhibited at a molar
ratio of antagonist to agonist of 1:1 (Fig. 5D). Thus, AGN
193109 is an effective antagonist of a ligand (9-cis-RA) that
interacts with high affinity with both RARs and RXRs which
bind the MCMV enhancer. AGN 193109 does not bind RXRs
and thus is unlikely to prevent 9-cis-RA from directly interact-
ing with RXRs. Note that as shown above, RXR ligands alone
are relatively inactive in stimulating the multiple RXR-RAR
heterodimers bound to the enhancer (Fig. 5A). Since the an-
tagonist (AGN 193109) binds with high affinity to RARs with-
out any agonist activity, AGN 193109 likely inhibits the 9-cis-
RA effect of the RAR partner of the heterodimer. We
therefore conclude that ligand activation of RAR is required
for mediating the transcriptional activation of the enhancer by
retinoids.
Since the growth rate of MCMV is affected by retinoids, we
also investigated whether activation of RAR is also necessary
for mediating the enhanced growth response. In these experi-
ments, NIH 3T3 cells were infected with MCMV at an MOI of
0.01 and treated with a fixed concentration of 9-cis-RA in the
presence of increasing concentrations of AGN193109. Figure
FIG. 4. Effect of RA on MCMV growth. (A) NIH 3T3 cells were exposed to 9-cis-RA at 1025 M (1RA) or vehicle (2RA) for 4 h. Subsequently, the cells were
infected with MCMV (Smith strain) at an MOI of 0.01 PFU/cell and reexposed to 9-cis-RA at 1025 M (1RA) or vehicle (2RA). At the different times after infection
indicated, the presence of extracellular virus in the cultures was determined. Each data point represents the average and standard deviation for three separate cultures.
Similar results were obtained with 1025 M ATRA (data not shown). dpi, days postinfection. (B) Same as panel A except that MCMV infections were carried out at
an MOI of 10. hpi, hours postinfection. (C) Same as panel A except that NIH 3T3 cells were infected with vaccinia virus at an MOI of 0.01 PFU/cell. In this case, the
presence of intracellular virus in the cultures was determined. (D) Same as panel A except that NIH 3T3 cells were infected with herpes simplex virus type 1 at an MOI
of 0.01 PFU/cell. Growth of herpes simplex virus type 2 in NIH 3T3 cells was also unaffected by treatment with 9-cis-RA at 1025 M (data not shown).
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FIG. 5. RAR activation in cells is required for mediating the induction of MCMV by RA. (A) NT-2/D1 cells were transfected with 5 mg of pON405 and incubated
for 36 h with the vehicle (2RA), 9-cis-RA (9cRA) at 1025 M, ATRA at 1025 M, TTNPB at 1027 M, LG100069 at 1027 M, or a combination of TTNPB and LG100069
at 1027 M each. Transfection efficiency was standardized by cotransfection of 5 mg of tkLuc. The response of pON405 to the different retinoids is plotted as the fold
induction of b-galactosidase activity observed in these experiments, calculated for each construct by taking the activity in the absence of RA as 1. Each bar represents
the average and standard deviation of triplicate determinations. (B) NIH 3T3 cells were exposed to 9-cis-RA at 1025 M, ATRA at 1025 M, TTNPB at 1027 M,
LG100069 at 1027 M, a combination of TTNPB and LG100069 at 1027 M each, or the vehicle (2RA) for 4 h. Subsequently, the cells were infected with MCMV
(RM461) at an MOI of 0.01 PFU/cell and reexposed to the different retinoids or the vehicle (2RA). On day 5 after infection, the presence of extracellular virus in
the cultures was determined. The fold enhancement of MCMV replication was calculated in each case by taking the amount of virus in the absence of RA as 1. Each
bar represents the average and standard deviation for three separate cultures. (C) Structure of the RAR antagonist. The 50% inhibitory concentrations of AGN 193109
are 9 (61) nM for RARa, 7 (63) nM for RARb, and 5 (61) nM for RARg. The 50% inhibitory concentrations were determined by performing transfection assays
on CV-1 cells with a reporter construct, MTV-4(R5G)-LUC, containing four copies of the DR-5 RARE R5G and expression plasmids for either RARa, -b, or -g and
using a 1028 M dose of ATRA (25). (D) NT-2/D1 cells were cotransfected with 5 mg of pON405 and incubated for 36 h with the vehicle or 1026 M 9-cis-RA in the
presence or absence of the indicated increasing concentrations of the retinoid antagonist AGN 193109 or the vehicle. Transfection efficiency was standardized by
cotransfection of 5 mg of tkLuc. b-Galactosidase activity is expressed as the normalized response, which is the b-galactosidase activity divided by the luciferase activity.
Activation obtained with 9-cis-RA treatment alone was considered 100%. The data presented are representative of results of triplicate experiments. (E) NIH 3T3 cells
were exposed to the vehicle or 9-cis-RA at 5 3 1025 M in the presence or absence of the indicated concentrations of the retinoid antagonist AGN 193109 or the vehicle.
Subsequently, cells were infected with MCMV (RM461) at an MOI of 0.01 PFU/cell and reexposed to the different retinoids. On day 5 after infection, the presence
of extracellular virus was determined. The amount of virus obtained with 9-cis-RA treatment alone was considered 100%. Each data point represents the average and
standard deviation for three separate cultures.
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5E clearly shows that AGN 193109 can effectively antagonize
the stimulatory effect of 9-cis-RA in a dose-responsive manner
where maximal antagonism is achieved at equimolar concen-
trations with 9-cis-RA. As expected, AGN 193109 also effec-
tively antagonized the ATRA-induced growth of MCMV (data
not shown). In the absence of exogenously added ATRA or
9-cis-RA, AGN 193109 did not result in any marked inhibition
of MCMV growth (data not shown), suggesting that AGN
193109 functions as a neutral antagonist under these condi-
tions of cell culture and infection. Taking the data together, we
conclude that RAR activation in cells is required for mediating
the effects of exogenous RA on MCMV.
Treatment of MCMV-infected animals with exogenous RA
selectively leads to more disease and increased susceptibility
to lethal infection. The pharmacokinetic properties of natural
retinoids have been the subject of several studies. For the
BALB/c mouse it has been shown that following a single initial
oral administration of ATRA, the plasma peak time of this
retinoid occurs between 1 and 3 h (1). When frequent doses of
ATRA are administered after the first dose, ATRA plasma
levels are reduced, indicating that intermittent dosing of this
retinoid, instead of a daily dosing, may better maintain long-
term plasma ATRA levels. On the basis of these observations,
we chose an administration regimen in which animals are ex-
posed to an initial dose of ATRA at 2 h prior to infection and
to subsequent doses every other day after infection. In these
experiments, then, infected animals were exposed to ATRA
for short pulses of time. In control experiments, uninfected
animals administered this level of ATRA on alternate days all
survived the treatment period and showed no overt signs of
illness (data not shown). Accordingly, as a first step to assess
whether exogenous ATRA treatment alters the susceptibility
to infection, 6-week-old BALB/c mice were inoculated with 105
PFU of MCMV and every other day were orally administered
50 mg of ATRA per kg in corn oil or given corn oil alone.
Under these conditions of infection, 83% of the control mice
survived the infection, whereas only 33% of the ATRA-treated
animals survived (Fig. 6A). To evaluate whether this effect was
specific to a pathogenic MCMV infection, we examined the
survival of ATRA-treated and untreated mice inoculated with
2 3 107 PFU of vaccinia virus. (Vaccinia virus is not influenced
by RA in tissue culture [Fig. 4C]). Figure 6B shows that 33 and
50% of the untreated and ATRA-treated animals, respectively,
survived vaccinia virus infection. These results suggest that oral
administration of ATRA can selectively increase the suscepti-
bility to a lethal MCMV infection.
To quantify what influence ATRA has on the outcome of an
MCMV infection, the LD50 was experimentally calculated. In
these experiments the LD50 was determined by the method of
Reed and Muench (42) (see Materials and Methods for de-
tails), using six mice per group with serial fivefold dilutions.
When titrated in control treated mice, 2 3 105 PFU of MCMV
was equivalent to one LD50, but when mice were treated with
ATRA during infection, only 6 3 104 PFU was equivalent to
one LD50. Furthermore, in an additional experiment using a
different stock of virus and serial onefold viral dilutions, iden-
tical results were obtained (Fig. 7). In this experiment, the
calculated LD50 was 2.34 3 10
5 for control treated mice and
6.27 3 104 for mice exposed to ATRA (Fig. 7). Thus, ATRA
treatment of MCMV-infected mice appears to mildly exacer-
bate an acute infection. To test whether the effects of ATRA
on the acute MCMV infection are mediated by activation of
RAR, AGN 193109 was coadministered with ATRA. In these
experiments, mice (six mice per group) were inoculated with
serial fivefold dilutions of virus, and each group was cotreated
with 50 and 25 mg of ATRA and RAR antagonist per kg,
respectively. The determined LD50 indicates that whereas the
dose of MCMV required to cause 50% mortality in mice
treated with ATRA was 6 3 104 PFU, the LD50 in mice
cotreated with ATRA and RAR antagonist was 5 3 105. These
results show that an RAR antagonist can block the ATRA-
induced effects in an acute infection, providing direct evidence
that these adverse effects are mediated by RARs. When AGN
193109 was administered to MCMV-infected mice, in the ab-
sence of exogenous ATRA, the determined LD50 did not sig-
nificantly increase in comparison with that for control infected
FIG. 6. Oral administration of ATRA selectively increases the susceptibility of mice to MCMV infection. BALB/c.ByJ mice (six per group) were pretreated by
intragastric intubation with vehicle (corn oil) (2RA) or 50 mg of ATRA per kg in vehicle (1RA) 2 h before intraperitoneal infection with 1 3 105 PFU of MCMV
(Smith strain) (A) or 2 3 107 PFU of vaccinia virus (VV) (B). Treatment with vehicle or ATRA in vehicle was repeated on days 2, 4, 7, 9, 11, and 14 after infection.
Mice were monitored daily for survival up to and including day 15. Survival curves were statistically analyzed by the log rank test and showed that RA treatment
significantly influenced the rate of mortality from MCMV (P value of 0.01) but not from vaccinia virus (P value of 0.64).
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mice (data not shown). Together, these results lead us to con-
clude that ligand activation of RARs can play a role in mod-
ulating an MCMV infection in vivo.
To determine whether the ATRA-treated mice undergo a
more severe infection due to elevated levels of virus, the
amount of infectious virus produced in the spleens of ATRA-
treated or control treated animals was determined. In these
experiments, control treated mice or those administered
ATRA were infected with 2 3 103 PFU of MCMV and sacri-
ficed at 4 days postinoculation. In correlation with the ATRA-
enhanced mortality, a trend of higher virus titers was observed
in the spleens of ATRA-treated animals in comparison with
control infected mice (Fig. 8A). In additional control experi-
ments, lymphocyte choriomeningitis virus-infected mice
treated with ATRA did not show any difference in viral spleen
titers in comparison with control infected mice (data not
shown), further indicating the selective effect of ATRA on
MCMV infection.
Pathological differences in the spleens of MCMV-infected
mice treated with ATRA were also noted. It has been previ-
ously reported that the severity of necrosis of the spleen ob-
served in BALB/c mice infected with MCMV correlates with
high levels of viral replication (37). In this mouse strain, a
hallmark of the severe necrosis inflicted by MCMV is the
marked reduction in splenic weight. Spleens from control
MCMV-infected mice were significantly (P , 0.05) larger than
those of the ATRA-treated MCMV-infected mice (Fig. 8B).
The increased sizes of spleens of the control treated animals is
due to a follicular lymphoid hyperplasia characteristic of a
mildly acute CMV infection (Fig. 9, top). In these spleens,
there is a paucity of readily identifiable cytomegalic cells (a
characteristic of a CMV-infected cell), and the red pulp has
well-defined hematopoietic erythroid and myeloid tissue and
shows no overt signs of necrosis (Fig. 9, top). By contrast, the
smaller spleens of the ATRA-treated animals are associated
with a marked absence of extramedullary hematopoietic tissue
and exhibit a high density of cytomegalic cells in the red pulp,
indicating an extensive infection of macrophages (Fig. 9, bot-
tom). In these spleens, multiple sites of necrosis were readily
apparent and appeared to be restricted to areas outside the
lymphoid cell population in tissue closely associated with cy-
tomegalic cells in the red pulp (Fig. 9, bottom). The pathologic
features manifested by these necrotic spleens are a hallmark of
a severe infection by MCMV. It is noteworthy that ATRA-
treated uninfected mice have spleens larger than those of un-
treated control mice due to increased hematopoiesis in the
spleen (32). These results show that ATRA-treated MCMV-
infected animals exhibit greater virus-induced spleen damage
than do untreated mice. We conclude from these experiments
that treatment of infected animals with exogenous ATRA dur-
ing the course of MCMV infection selectively leads to more
disease and increased susceptibility to infection.
DISCUSSION
The impact of molecular signals that engage and cointegrate
specific intracellular signalling pathways with an infectious pro-
gram of a virus is not well understood. We have addressed this
issue by investigating the susceptibility of a member of the
CMV family of viruses, MCMV, to retinoids in tissue culture
and in an experimental animal model. Our report describes the
ability of a ligand-activated RAR pathway to modulate an
acute viral infection. We further demonstrate that an RAR
antagonist can efficiently inhibit an RA-induced CMV infec-
tion in vitro and in vivo.
RA modulation of MCMV in vitro. The activation of the
RAR pathway by exogenous synthetic or natural RA analogs
leads to a dramatic stimulation of MCMV growth in NIH 3T3
cells. This response appears to be selective for MCMV, as the
growth of vaccinia virus or herpes simplex virus in NIH 3T3
FIG. 7. Levels of lethality of MCMV in mice treated with ATRA and those
treated with solvent alone. BALB/c.ByJ mice were pretreated by intragastric
intubation with vehicle (corn oil) (2RA) or 50 mg of ATRA per kg in vehicle
(1RA) 2 h before intraperitoneal infection with different doses of MCMV
(Smith strain). Treatment with vehicle or ATRA in vehicle was repeated on days
2, 4, 7, 9, 11, and 14 after infection. Mice were monitored daily for survival up to
and including day 15. Logit regression curves relating survival to the log (to the
base 10) dose of virus were fit to each group (deviance 5 2.10 and P 5 0.95 for
the control treated mice; deviance 5 6.80 and P 5 0.56 for the mice treated with
RA). The points indicate the observed survival at each dose, with the integers
above the points denoting the numbers of animals tested at that dose. The LD50
for each group was estimated from the fitted logit regression line as 6.27 3 104
for the group of mice treated with RA and 2.34 3 105 for the control group. The
bars along the x axis represent approximate 95% confidence intervals for the
LD50s. A formal test of the equivalence of the LD50s for the two groups would
be rejected at an alpha level of less than 0.001.
FIG. 8. Oral administration of ATRA increases the severity of an MCMV
infection in the spleens of infected mice. BALB/c.ByJ mice (five per group) were
pretreated by intragastric intubation with vehicle (2RA) or 50 mg of ATRA per
kg (1RA) 2 h before intraperitoneal infection of 5 3 103 PFU of MCMV (Smith
strain). Treatment with vehicle or ATRA was repeated on day 2 after infection.
All mice were sacrificed on day 4 after infection for determination of virus titers
(A) and spleen weight (B). There was a trend in higher viral titers in the spleens
of the ATRA-treated animals in comparison with control treated mice (P value
of ;0.05) as analyzed by the Mann-Whitney test (two tailed). Spleen weights
were also significantly different (P , 0.05) as determined by Student’s t test
(two-tailed). Error bars indicate standard deviations.
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cells is unaffected by RA administration. Vaccinia virus repli-
cates in the cytoplasm and is thus not expected to be influenced
by the action of nuclear hormone receptors. By contrast, rep-
lication of herpes simplex virus takes place in the nucleus;
however, to date functional RAREs in its genome have not
been described. Most importantly, our study shows that
MCMV growth enhancement by RA can be completely inhib-
ited by cotreatment with an RAR antagonist, demonstrating
that activation of RAR is essential for mediating this response.
We also found that RA induced the MCMV enhancer and that
this activation could also be inhibited by an RAR antagonist.
The detailed molecular mechanism by which RAR promotes
the growth of MCMV remains to be determined. One possi-
bility is that ligand-activated RARs initiate a cascade of gene
expression by directly stimulating key regulatory genes of the
virus. For instance, the observation that the enhancer of
MCMV contains at least seven RAREs of the DR2 configu-
ration is consistent with this possibility. Alternatively, RARs
may activate host-encoded genes that subsequently play a role
in promoting viral expression. Yet another possibility is that
RAR indirectly promotes viral expression and replication by
altering coregulatory molecules or perhaps the organization of
virus-associated chromatin. While it is conceivable that any or
all of these possibilities coordinate the growth enhancement of
MCMV, all have in common a single transduction mediator,
RAR. In principle, then, the activation or inhibition of the
RAR pathway now provides a molecular basis for potentially
modulating a CMV infection.
RA modulation of MCMV in vivo. The MCMV model sys-
tem enabled us to investigate contributions of exogenous RA
to infected animals. This scenerio was tested in healthy adult
mice challenged with an MCMV infection. In these experi-
ments ATRA was orally administered on alternate days to
infected animals during the course of the infection. In this
dosage regimen, the infected animals are exposed to transient
levels of exogenous ATRA lasting ;1 to 3 h in the first dose,
while in the subsequent doses ATRA persists with progres-
sively shorter intervals due to homeostatic control in maintain-
ing physiological levels of the natural retinoid. On the basis of
several criteria, including determination of the amount of virus
required to cause death, pathological changes in the spleen,
and amount of infectious virus, we conclude that exogenous
ATRA can exacerbate an MCMV infection. While the magni-
tudes of these various effects were not dramatic, they were
significant. This is perhaps not an unexpected outcome, due to
the poor pharmacokinetics of ATRA and the full immune
competence of the animals. Indeed, the primary control of
viral growth at these times of infection involves both the innate
and specific immune responses (27). In this connection it is
worth noting that immune molecules (such as interferon) that
are known to play a major role in controlling a viral infection
in vivo when administered systemically only moderately influ-
ence the outcome of an infection. We cannot exclude the
possibility that the effects of exogenous ATRA on the MCMV
infection in vivo are due to an unrelated mechanism such as
alteration of immune effector functions. However, this possi-
bility seems unlikely, since other pathogenic viruses such as
lymphocyte choriomeningitis virus and vaccinia virus are not
affected by exogenous ATRA. In addition, the effects we ob-
serve in vivo are consistent with the ability of ATRA to aug-
ment an MCMV infection in vitro. Importantly, by blocking
the action of RA with an antagonist, we show that activation of
RAR in vivo is necessary for mediating the response of MCMV
to RA.
Conservation of RA responses between MCMV and HCMV.
The CMV family is highly species specific and is believed to
have evolved by ancient cospeciation with the respective hosts.
The time of divergence of MCMV and HCMV has been esti-
mated to be around 83 million years ago (36). Thus, conser-
vation of sequence or function is likely to signify biological
significance. As highlighted in the introduction, HCMV is
known to have its growth rate influenced equally by ATRA and
9-cis-RA, and it contains within its enhancer multiple RAREs.
In the case of the HCMV enhancer there are fewer elements
(one DR2 and two DR5s), which bind RXR-RAR het-
erodimers with affinities of 5, 10, and 20 nM (6). Interestingly,
the MCMV and HCMV enhancers appear to respond to RA to
the same level of activation. This similar response may be
explained by their affinity for binding the receptors. Thus,
while the HCMV enhancer has fewer RAREs than the MCMV
enhancer, the elements bind more tightly to the receptors.
Studies with HCMV indicate that the action of RA is relatively
complex, involving multiple modes of action (20). Similarly, for
MCMV the molecular and cellular basis of the response to RA
is likely to be multifactorial, involving both direct and indirect
effects. While further studies are required to determine the
precise mechanism by which RA exerts its effects, it is clear
that the analyses described here reveal a conservation in the
responses of MCMV and HCMV to RA.
Practical implications. The increasing use of high doses of
retinoids in chemotherapy and the future availability of even
FIG. 9. Oral administration of ATRA enhances MCMV damage in the
spleens of infected mice. Splenic sections from BALB/c.ByJ mice treated by
intragastric intubation with vehicle (2RA) or with 50 mg of ATRA per kg
(1RA) and infected with 5 3 103 PFU of MCMV for 4 days are shown.
Magnification, 3100. Some of the cytomegalic cells present are indicated by
arrowheads, and the areas of necrosis are indicated by arrows. The presence of
selected hematopoietic cells, such as megakaryocytes (M), is shown. The red pulp
(RP) and white pulp (WP) are indicated.
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more potent synthetic retinoids may make CMV infections a
potential complication of retinoid therapy with RAR agonists.
At present it is not known whether high doses of retinoids can
lead to clinical CMV infections, although to our knowledge the
high-risk immunosuppressed patients have not yet been given
retinoid therapy. For MCMV, the magnitudes of the in vivo
effects were significant but much lower than those observed in
tissue culture. Thus, the ability of exogenous treatment with
retinoids to affect humans infected with CMV may be measur-
able but similarly low. In the future, if retinoids prove to be a
risk factor for virus infection in the clinical setting, then reti-
noid antagonists could have significant therapeutic value.
Again, experiments with the MCMV animal model system
show that cotreatment of RA-treated animals with an RAR
antagonist can protect against an exacerbated infection. These
results also raise the possibility that RAR antagonists might
have practical potential for viruses other than CMV.
In conclusion, ligand activation of a nuclear receptor signal-
ling pathway, the RAR pathway, can alter the outcome of in
vitro and in vivo infections by MCMV. Considering that a
number of viruses (e.g., hepatitis B virus, mouse mammary
tumor virus, simian virus 40, and human polyomavirus BK)
contain functional binding sites that enable hormonal control
of expression (18, 20, 39, 41, 43, 53, 54), it seems likely that
regulation of an infectious program by signalling molecules
and intracellular receptors may be more widespread. If so, this
adaptation may represent an important principle in viral
growth control mechanisms outside the immune system.
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